NOVAVAX INC Unrecognized Tax Benefits that Would Impact Effective Tax Rate
NOVAVAX INC (NVAX) had Unrecognized Tax Benefits that Would Impact Effective Tax Rate of $4.00 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate · last filed 2026-02-26
- 2025-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $4.00M.
- 2024-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $4.10M.
- 2023-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $4.20M.
- 2022-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $5.19M; Unrecognized Tax Benefits that Would Impact Effective Tax Rate as first filed $5.20M.
| Period end | Unrecognized Tax Benefits that Would Impact Effective Tax Rate | Unrecognized Tax Benefits that Would Impact Effective Tax Rate as first filed |
|---|---|---|
| 2025-12-31 | $4.00M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $4.10M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $4.20M 10-K · filed 2025-02-27 | |
| 2022-12-31 | $5.19M 10-K · filed 2024-02-28 | $5.20M 10-K · filed 2023-02-28 |
| 2021-12-31 | $11.20M 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |